MedCity News

JULY 24, 2023

In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5% Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025.

Patients 98

Patients FDA Biopharma 98

Medical Device Success

DECEMBER 18, 2011

This is normal for this time of the year as company leaders look to 2012. Hopefully, most of you are already in control of your 2012 plans. Good luck as you prepare for 2012! If you have struggled in 2011, let me know, perhaps I can share some ideas for success. If not, the posts listed above may help you get on track.

Medical 100

Medical Sales Marketing Consulting 100

World of DTC Marketing

MARCH 27, 2022

The national rate of suicidal ideation among adults has increased every year since 2011-2012. Suicidal ideation continues to increase among adults in the U.S. 4.58% of adults report having serious thoughts of suicide, an increase of 664,000 people from last year’s dataset. who are going untreated.

Healthcare 259

Healthcare Healthcare Insurance Patients 259

World of DTC Marketing

MARCH 23, 2022

The program was codified into law under the Food and Drug Safety and Innovation Act (FDASIA) in 2012. Accelerated Approval was developed in 1992 in response to the HIV/AIDS crisis and has led to expedited drug and biologic approvals in several disease areas across the FDA.

Patients 200

Patients FDA Doctors Physicians 200

Clarivate

OCTOBER 7, 2021

Every year since 2012, Clarivate has identified the Top 100 Global Innovators. In this episode of Ideas to Innovation , we welcome Bernhard Quendt of Thales, one of the world’s Top 100 Global Innovators. Listen to the podcast.

Leads 98

Leads 98

Legacy MEDSearch

MAY 3, 2023

Leadership includes Joy Celebre (recruiting since 1996, joined in 2008), Carolyn Jones (recruiting since 1995, joined in 2011), Arshad Alam (recruiting since 1995, joined 2017), John White (Talent Sourcing Manager, joined 2012), and Partner Chris Miclot, (joined 2012). “In

Recruitment 98

Recruitment Medical Management Media 98

pharmaphorum

JULY 22, 2022

The CMA delivered a preliminary judgment in the case last year which concluded that Pfizer and Flynn abused a dominant position in phenytoin sodium capsules, causing NHS spending on the drug to balloon from around £2 million a year in 2012 to £50 million the following year.

Competition 111

Competition Pharma Marketing Patients 111

World of DTC Marketing

SEPTEMBER 29, 2021

According to the CDC, in 2012, 25.5% I learned later that he was being treated for a severe form of COPD, which had affected his life so much his wife said, “he just doesn’t do the things he used to anymore” Paul is not alone. of US adults had multiple (?2)

Patients 199

Patients Side effects Doctors Healthcare 199

European Pharmaceutical Review

JANUARY 16, 2023

The Food and Drug Administration Safety and Innovation Act, enacted in 2012, permitted the FDA to enter into agreements to recognise drug inspections conducted by foreign regulatory authorities determined to be capable of conducting inspections that meet US requirements.

Food and Drug Administration 122

Food and Drug Administration FDA Manufacturing Food 122

European Pharmaceutical Review

APRIL 27, 2023

AAVs evolving the in vivo gene therapy space In 2012, the European Medicines Agency (EMA) approved the first AAV gene therapy, Glybera (Alipogene tiparvovec). Achieving this in the relatively new and dynamic CGT regulatory landscape will rely on flexible and agile developers and manufacturers.

Biopharma 98

Biopharma Medicine Manufacturing Patients 98

European Pharmaceutical Review

DECEMBER 21, 2022

The US Food and Drug Administration (FDA) created live biotherapeutic products (LBP) as a new category in the 2012 guidelines. 1 It defined LBPs as drug products containing live microorganism(s) to be used to prevent, treat or cure a disease or condition in human beings.

Food and Drug Administration 111

Food and Drug Administration FDA Medicine Government 111

pharmaphorum

NOVEMBER 11, 2022

Black/African American participation in trials has been declining over the past decade, says the report, falling from around 12% in 2012 to less than 10% in 2019 and 2020. For Hispanics, participation in trials increased from 7% in 2012 to a high of just under 10% in 2017 but fell back to levels of around 8% to 9% in the past two years.

Recruitment 97

Recruitment Pharma Education FDA 97

European Pharmaceutical Review

FEBRUARY 29, 2024

and Genmab A/S made an agreement in August 2012, in which Janssen would be granted an exclusive license to develop, manufacture and commercialise daratumumab. ” The Janssen Pharmaceutical Companies of Johnson & Johnson noted that Janssen Biotech, Inc.

Pharmaceutical 105

Pharmaceutical Manufacturing Patients 105

Pharmaceutical Technology

AUGUST 2, 2024

Alemtuzumab, under the brand name Campath, was pulled from the leukaemia market by Sanofi in 2012.

FDA 52

FDA Marketing 52

Pharmaceutical Technology

AUGUST 7, 2024

Precigen also plans to raise $30m to focus on advancing its recurrent respiratory papillomatosis (RRP) candidate PRGN-2012.

52

52

Pharmaceutical Technology

SEPTEMBER 4, 2024

Between 2012 and 2021, outsourcing propensity for FDA NDA injectables approvals averaged 40%, according to GlobalData’s Contract Injectable Packaging Trends…

FDA 52

FDA 52

European Pharmaceutical Review

FEBRUARY 27, 2024

In 2012, Dame June was elected as the first chair of the European Pharmacovigilance Risk Assessment Committee, MHRA added. Her educational background includes training in medicine in Oxford after completing a master’s degree by research in Pharmacology.

Safety 111

Safety Pharmacology Medicine Management 111

European Pharmaceutical Review

APRIL 27, 2023

Growth has been rapid since Europe’s first gene therapy approval in 2012, 2 and the first US Food and Drug Administration (FDA) approval of a gene therapy in 2017. 3 Any sector would struggle to keep up with expansion of this speed, but the inherent difficulty of working with and producing biologics adds another layer of complexity.

Manufacturing 97

Manufacturing Food and Drug Administration Pharmaceutical products Food 97

World of DTC Marketing

JUNE 3, 2022

The idea that hackers might target people’s implantable cardiac devices was popularised in a 2012 episode of the US television drama ‘Homeland,’ in which terrorists hacked a fictional vice president’s pacemaker and killed him. Hacking medical devices remotely. It is not just VIPs (or VPs) who need to worry about this.

Doctors 291

Doctors Insurance Medical Patients 291

European Pharmaceutical Review

JULY 20, 2022

Our research looked at products that were voluntarily withdrawn, or had their licence revoked or suspended within the EU for a safety reason between 2012 and 2016. The Human Medicines Regulations 2012, UK statutory instruments, 2012 No 1916, PART 5, Revocation, variation and suspension of marketing authorisation. Study focus.

Medicine 97

Medicine Safety Side effects Electronics 97

European Pharmaceutical Review

DECEMBER 14, 2023

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 Lane S, Lynn E, Shakir S.

Medicine 116

Medicine Safety Competition Medical 116

Pharmaceutical Technology

MAY 10, 2023

The FDA approved Truvada as the first PrEP treatment in July 2012, with Descovy receiving a nod for this use in October 2019. Gilead markets both Truvada and its successor Descovy. While both Descovy and Truvada contain emtricitabine, they feature different forms of the antiviral tenofovir.

Government 105

Government FDA Pharmaceutical Sales 105

European Pharmaceutical Review

JUNE 7, 2023

Supporting the UK’s cell and gene therapy industry Since 2012, there has been over £5.5 Additionally, a team of technical and clinical adoption experts based in offices at the site will work closely with collaborators to help them bring cell therapies to clinical trials and the market.

Medicine 98

Medicine Manufacturing Marketing Pharmaceutical 98

European Pharmaceutical Review

NOVEMBER 22, 2023

Since most patients have an initial response to the treatment, 80 percent will experience recurrence and require subsequent therapies, according to a 2012 paper published in Annals of Oncology.

Consulting 98

Consulting Patients Networking Safety 98

Pharmacy Times

AUGUST 17, 2022

Analysis looks at those with arthritis, chronic pain, headaches, lower back pain, and neuropathic pain between 2012 and 2019.

Prescription 49

Prescription Patients 49

European Pharmaceutical Review

FEBRUARY 10, 2023

Since its opening in 2012, occupier companies have secured £2.9bn in finance, making the cluster one of the most attractive for investment in biotechnology in the UK. It provides companies access to specialist equipment, mentoring and finance suited to their stage of development.

Manufacturing 98

Manufacturing Leads Medicine Healthcare 98

European Pharmaceutical Review

JULY 4, 2024

2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 14 Marketing authorisation In the UK, medicinal products placed on the market are required to have marketing authorisations in accordance with The Human Medicines Regulations 2012 (S.I. 2012/1916).

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

pharmaphorum

OCTOBER 26, 2022

The two drugmakers were fined in July, after the CMA upheld a preliminary judgment that Pfizer and Flynn had abused a dominant position in phenytoin sodium capsules, causing NHS spending on the drug to swell from around £2 million a year in 2012 to £50 million the following year.

Competition 105

Competition Marketing Pharma Medicine 105

European Pharmaceutical Review

OCTOBER 10, 2022

Since 2012, the CDC has recommended the vaccine series during the third trimester of each pregnancy. The endorsement therefore demonstrates significant progress in the industry’s ability to combat the disease in the younger population.

FDA 105

FDA Food and Drug Administration Side effects Food 105

CloserIQ

OCTOBER 10, 2018

Founded 2012. Founded 2012. Founded 2012. Founded 2012. Founded 2012. Founded 2012. They are seeking to transform the automobile industry and are known for a fast-paced, collaborative work environment. Employees have characterized the culture as challenging and supportive. ProfitWell. 11-50 employees. $10

Sales 76

Sales Management Marketing Education 76

ProSellus

JULY 18, 2018

What’s more, since 2012 and 2016 (the time frame of […]. In fact, in a 2017 report for the nonprofit Physician Advocacy Institute, revealed that 5,000 physician practices and over 14,000 physicians have been ‘scooped up’ by hospitals between July 2015 and July 2016 alone. appeared first on ProSellus.

Physicians 52

Physicians 52

Pharmaceutical Technology

MAY 26, 2023

While the market was worth over $6 billion in 2012, this has now grown to nearly $48 billion only a decade later, said Avigayil Chalk, PhD, GlobalData’s Senior Oncology and Haematology analyst, at an immuno-oncology webinar held on May 23.

Marketing 105

Marketing Physicians Insurance Pharmaceutical 105

Medico Reach

AUGUST 12, 2022

billion In operation since: 2012 Devoted Health aims to make healthcare more accessible and more affordable. Here is a list of CEOs from the industry who are now billionaires. Company: Devoted Health Age: 52 years (1970 born) Net worth: $1.9 billion Company evaluation: $12.7

Healthcare 98

Healthcare Healthcare Healthcare Provider Engineering 98

pharmaphorum

SEPTEMBER 26, 2022

Other drugs used to treat ATL include Kyowa Kirin’s amti-CCR4 antibody Poteligeo (mogamulizumab), cleared by the MHLW for CCR4-positive ATL in 2012, as well as Bristol-Myers Squibb/Celgene’s oral therapy Revlimid (lenalidomide), which got a green light there five years ago.

Patients 98

Patients Medicine FDA Medical 98

European Pharmaceutical Review

MARCH 16, 2023

Ivacaftor – a breakthrough treatment The approval of IVA in 2012 marked a breakthrough in treating the disease. This is important for those with F508del, as it can increase the quantity of protein at the cell surface, where it can now be acted upon by IVA.

Patients 98

Patients Safety Leads Medical 98

Pharma Marketing Network

JULY 17, 2023

Anna was named a Top 100 PharmaVoice “most inspiring leader” in 2012. With Anna at the helm, MedEvoke has quickly become a leading partner to many top-20 pharmaceutical corporations.

Networking 52

Networking Pharma Healthcare Healthcare 52

pharmaphorum

JULY 15, 2022

Amarin first introduced its drug in the US as Vascepa in 2012, but only made it available in Europe last year, starting with a German launch last September. .” NHS England has estimated that between 25% and 35% of people having statin therapy have elevated triglycerides.

Patients 98

Patients Competition Marketing Medicine 98